Literature DB >> 8128486

The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression.

R N Hines1, J R Cashman, R M Philpot, D E Williams, D M Ziegler.   

Abstract

The flavin-containing monooxygenase (FMO) has been characterized in several mammalian species, including human. The FMO forms a stable NADP(H)- and oxygen-dependent 4 alpha-hydroperoxy flavin enzyme intermediate in the absence of an oxygenatable substrate. As such, substrate specificity appears to be controlled by access to this stabilized intermediate, resulting in this enzyme's ability to metabolize a wide variety of xenobiotics. These include tertiary and secondary alkyl- and arylamines, many hydrazines, thiocarbamides, thioamides, sulfides, disulfides, thiols, and other soft nucleophiles. Although some of these compounds are oxidized to less active derivatives, several examples of metabolic activation to potentially toxic intermediates also exist. Mercapto-pyrimidines and thiocarbamides, for example, appear to be activated predominantly by FMO. Thus, this enzyme system may play an important role in the early steps of chemical toxicity. Often, the contribution of FMO to the metabolism of a given compound can be assessed by its unique stereoselectivity relative to other oxygenases. For example, the cytochromes P450 oxidize (S)-nicotine to a mixture of cis- and trans-N-1'-oxides. In contrast, (S)-nicotine is oxidized by human FMO3 exclusively to the trans-N-1'-oxide. With the purification and cloning of FMO from multiple tissues and species it became apparent that more than one FMO exists. Further, there are considerable tissue- and species-specific differences in FMO expression that likely contribute to observed differences in detoxication competency and toxicant susceptibility.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8128486     DOI: 10.1006/taap.1994.1042

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  12 in total

1.  Molecular phylogeny, long-term evolution, and functional divergence of flavin-containing monooxygenases.

Authors:  Da Cheng Hao; Shi Lin Chen; Jun Mu; Pei Gen Xiao
Journal:  Genetica       Date:  2009-07-05       Impact factor: 1.082

Review 2.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

3.  Molecular cloning, sequence characterization, SNP detection, and tissue expression analysis of duck FMO3 gene.

Authors:  Peng Wang; Jiangxia Zheng; Lujiang Qu; Ling Lian; Guiyun Xu; Ning Yang
Journal:  Mol Cell Biochem       Date:  2013-04-28       Impact factor: 3.396

4.  Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.

Authors:  Jin Won Sung; Hwi-Yeol Yun; Sunny Park; Young Ju Kim; Jeong Yee; Kyung Eun Lee; Byungjeong Song; Jee Eun Chung; Hye Sun Gwak
Journal:  Pharm Res       Date:  2020-01-28       Impact factor: 4.200

5.  Flavin-containing monooxygenase mRNA levels are up-regulated in als brain areas in SOD1-mutant mice.

Authors:  Stella Gagliardi; Paolo Ogliari; Annalisa Davin; Manuel Corato; Emanuela Cova; Kenneth Abel; John R Cashman; Mauro Ceroni; Cristina Cereda
Journal:  Neurotox Res       Date:  2010-11-17       Impact factor: 3.911

6.  Short-term calorie restriction feminizes the mRNA profiles of drug metabolizing enzymes and transporters in livers of mice.

Authors:  Zidong Donna Fu; Curtis D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  2013-11-13       Impact factor: 4.219

7.  Differential localization of flavin-containing monooxygenase (FMO) isoforms 1, 3, and 4 in rat liver and kidney and evidence for expression of FMO4 in mouse, rat, and human liver and kidney microsomes.

Authors:  Rachel M Novick; Ann M Mitzey; Mark S Brownfield; Adnan A Elfarra
Journal:  J Pharmacol Exp Ther       Date:  2009-03-23       Impact factor: 4.030

Review 8.  Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.

Authors:  A Hirvonen
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

9.  6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3.

Authors:  Shufeng Zhou; Philip Kestell; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jul-Sep       Impact factor: 2.569

10.  Age-related changes in hepatic activity and expression of detoxification enzymes in male rats.

Authors:  Erika Vyskočilová; Barbora Szotáková; Lenka Skálová; Hana Bártíková; Jitka Hlaváčová; Iva Boušová
Journal:  Biomed Res Int       Date:  2013-07-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.